127 related articles for article (PubMed ID: 25445209)
1. Ubiquitin-specific peptidase 22 overexpression may promote cancer progression and poor prognosis in human gastric carcinoma.
He Y; Jin YJ; Zhang YH; Meng HX; Zhao BS; Jiang Y; Zhu JW; Liang GY; Kong D; Jin XM
Transl Res; 2015 Mar; 165(3):407-16. PubMed ID: 25445209
[TBL] [Abstract][Full Text] [Related]
2. Is co-expression of USP22 and HSP90 more effective in predicting prognosis of gastric cancer?
Zheng H; Yu J; Li W; Yang D; Gao C; Zhang Q; Xu L
Pathol Res Pract; 2019 Apr; 215(4):653-659. PubMed ID: 30598339
[TBL] [Abstract][Full Text] [Related]
3. The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma.
Yang DD; Cui BB; Sun LY; Zheng HQ; Huang Q; Tong JX; Zhang QF
Cell Biochem Biophys; 2011 Dec; 61(3):703-10. PubMed ID: 21735131
[TBL] [Abstract][Full Text] [Related]
4. USP22 maintains gastric cancer stem cell stemness and promotes gastric cancer progression by stabilizing BMI1 protein.
Ma Y; Fu HL; Wang Z; Huang H; Ni J; Song J; Xia Y; Jin WL; Cui DX
Oncotarget; 2017 May; 8(20):33329-33342. PubMed ID: 28415621
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer.
Liu YL; Yang YM; Xu H; Dong XS
J Gastroenterol Hepatol; 2010 Nov; 25(11):1800-5. PubMed ID: 21039844
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic USP22 supports gastric cancer growth and metastasis by activating c-Myc/NAMPT/SIRT1-dependent FOXO1 and YAP signaling.
Liu H; Liu N; Zhao Y; Zhu X; Wang C; Liu Q; Gao C; Zhao X; Li J
Aging (Albany NY); 2019 Nov; 11(21):9643-9660. PubMed ID: 31689236
[TBL] [Abstract][Full Text] [Related]
7. Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic activity in mammalian and breast cancer cells.
Kim D; Hong A; Park HI; Shin WH; Yoo L; Jeon SJ; Chung KC
J Cell Physiol; 2017 Dec; 232(12):3664-3676. PubMed ID: 28160502
[TBL] [Abstract][Full Text] [Related]
8. USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway.
Liu YL; Jiang SX; Yang YM; Xu H; Liu JL; Wang XS
Cell Biochem Biophys; 2012 Jan; 62(1):229-35. PubMed ID: 21928107
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer.
Ning J; Zhang J; Liu W; Lang Y; Xue Y; Xu S
Eur J Histochem; 2012 Nov; 56(4):e46. PubMed ID: 23361242
[TBL] [Abstract][Full Text] [Related]
10. USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma.
Ning Z; Wang A; Liang J; Xie Y; Liu J; Feng L; Yan Q; Wang Z
Int J Oncol; 2014 Oct; 45(4):1594-608. PubMed ID: 24993031
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma.
Piao S; Ma J; Wang W; Liu Y; Zhang M; Chen H; Guo F; Zhang B; Guo F
Oral Oncol; 2013 Aug; 49(8):796-801. PubMed ID: 23664741
[TBL] [Abstract][Full Text] [Related]
12. USP22 drives colorectal cancer invasion and metastasis via epithelial-mesenchymal transition by activating AP4.
Li Y; Yang Y; Li J; Liu H; Chen F; Li B; Cui B; Liu Y
Oncotarget; 2017 May; 8(20):32683-32695. PubMed ID: 28427243
[TBL] [Abstract][Full Text] [Related]
13. USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt.
Zhang J; Luo N; Tian Y; Li J; Yang X; Yin H; Xiao C; Sheng J; Li Y; Tang B; Li R
Oncotarget; 2017 Apr; 8(15):24728-24740. PubMed ID: 28445968
[TBL] [Abstract][Full Text] [Related]
14. USP22 promotes tumor progression and induces epithelial-mesenchymal transition in lung adenocarcinoma.
Hu J; Yang D; Zhang H; Liu W; Zhao Y; Lu H; Meng Q; Pang H; Chen X; Liu Y; Cai L
Lung Cancer; 2015 Jun; 88(3):239-45. PubMed ID: 25907317
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics.
Yang M; Liu YD; Wang YY; Liu TB; Ge TT; Lou G
Tumour Biol; 2014 Feb; 35(2):929-34. PubMed ID: 23979981
[TBL] [Abstract][Full Text] [Related]
16. Decreased H2B monoubiquitination and overexpression of ubiquitin-specific protease enzyme 22 in malignant colon carcinoma.
Wang Z; Zhu L; Guo T; Wang Y; Yang J
Hum Pathol; 2015 Jul; 46(7):1006-14. PubMed ID: 25971547
[TBL] [Abstract][Full Text] [Related]
17. High USP22 expression indicates poor prognosis in hepatocellular carcinoma.
Tang B; Tang F; Li B; Yuan S; Xu Q; Tomlinson S; Jin J; Hu W; He S
Oncotarget; 2015 May; 6(14):12654-67. PubMed ID: 25909224
[TBL] [Abstract][Full Text] [Related]
18. [Expression of cancer stem cell marker USP22 in laryngeal squamous cell carcinoma].
Li L; Wen S; Wang B; Gao W; Zhang W; Meng X; Yang L; Kong L
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jun; 49(6):479-82. PubMed ID: 25241865
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin-specific protease 22: a novel molecular biomarker in glioma prognosis and therapeutics.
Liang J; Zhang X; Xie S; Zhou X; Shi Q; Hu J; Wang W; Qi W; Yu R
Med Oncol; 2014 Apr; 31(4):899. PubMed ID: 24573640
[TBL] [Abstract][Full Text] [Related]
20. Targeted eradication of gastric cancer stem cells by CD44 targeting USP22 small interfering RNA-loaded nanoliposomes.
Yang F; Zheng Z; Xue X; Zheng L; Qin J; Li H; Zhou Y; Fang G
Future Oncol; 2019 Jan; 15(3):281-295. PubMed ID: 30543303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
